Adam Cuker, MD, on Higher Efficacy of Gene Therapy Over SOC in Hemophilia B

The associate professor of medicine at University of Pennsylvania discussed new data from the BENEGENE-2 study of fidanacogene elaparvovec.

“I think fidanacogene elaparvovec is promising for a couple of reasons. We see that with a single infusion there was superiority to standard-of-care in reducing bleeds, and there were no worrisome safety signals that emerged. This appeared to be a durable response over 24 months, but of course, longer-term follow-up is needed. We hope for, essentially, a cure for hemophilia with gene therapy. And based on these results, preliminary though they are, they're a very encouragingstep toward that goal.”

A single infusion treatment of fidanacogeneelaparvovec demonstrated superiority over standard-of-care factor IX therapy in reducing annualized bleeding rates (ABR) in patients with hemophilia B, according to updated data from Pfizer’s BENEGENE-2 phase 3 clinical trial (NCT03861273). Compared with a 6-month lead-in period, patients treated with the therapy had a 78% reduction in ABR for treated bleeds (P = .0001)and a 92% reduction in the annualized infusion rate of exogenous FIX following infusion with fidanacogene elaparvovec (P <.0001).

CGTLive spoke with study investigator Adam Cuker, MD, associate professor of medicine, University of Pennsylvania, to learn more about BENEGENE-2 and the new superiority data. He also touched on the positive durability data seen in patients treated with fidanacogeneelaparvovec.

Pfizer announces positive top-line results from phase 3 study of hemophilia B gene therapy candidate. News release. Pfizer. December 20, 2023.
Related Videos
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
Related Content
© 2023 MJH Life Sciences

All rights reserved.